Andrew Tutt is Director of the Breast Cancer Now Research Unit at King’s College London and Honorary Consultant Clinical Oncologist, Breast Unit, GSTT.   Professor Tutt is also Professor of Breast Oncology and Head of Division of Breast Cancer Research and Director Breast Cancer Now Toby Robins Research Centre  at the Institute of Cancer Research.  He qualified in medicine from Bristol University in 1990. After postgraduate training in general medicine he trained in clinical oncology at the Royal Marsden Hospital before gaining a Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory at The Institute of Cancer Research. Here he worked on functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002. He cares for women with breast cancer as an oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust and is a member of St Gallen Early Breast Cancer International Consensus Panel developing international treatment guidelines. Professor Tutt is a faculty member of the section of Research Oncology at King’s College London School of Medicine and has been a Visiting Professor at British Columbia Cancer Agency and Jean Lubrano Visiting Scholar at Harvard Medical School.

Professor Tutt has, in collaboration with Professor Ashworth, developed a translational and clinical trial programme focusing on Triple Negative forms of Breast Cancer and cancers associated with functional deficiencies in BRCA1 and BRCA2. He has published papers from these programmes in the journals Nature, The New England Journal of Medicine, The Lancet and the Journal of Clinical Oncology. He is currently Chief Investigator for the UKCRN Triple Negative Trial actively recruiting in 65 Cancer Units around the UK, and is co-lead for a Triple Negative Breast Cancer Trial initiative for the Breast International Group. As Director of the Breakthrough Breast Cancer Research Unit at KCL Professor Tutt leads a laboratory programme aimed at the discovery and validation of biomarkers and potential therapy targets for Triple Negative Breast Cancer. He also advises Cancer Research UK and Cancer Research Technology on cancer therapy discovery as a member of the Discovery Committee.